Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-729 + NA + Peg-IFNα-2a in Chronic Hepatitis B
NCT04980482Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Oct 2021
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 7
01
Overview
A Phase 2 trial of imdusiran in Chronic Hepatitis B (CHB), sponsored by Arbutus Biopharma Corporation. Started Oct 2021; status: completed.
02
Drugs
imdusiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04980482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980482.